Abuse-deterrent dosage forms containing esketamine
AssigneeClexio Biosciences Ltd.
InventorsDerek Moe, Randal Seburg, Sagar Rane
Life of this patent
Estimating the term…
Loading patent…
AssigneeClexio Biosciences Ltd.
InventorsDerek Moe, Randal Seburg, Sagar Rane
Estimating the term…
Disclosed herein are immediate release oral dosage forms that contain abuse-deterrent and abuse-resistant features. In particular, the disclosed dosage forms can provide deterrence of abuse by ingestion of multiple individual doses. The disclosed dosage forms can likewise provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses. The dosage forms may also exhibit abuse resistant properties when physically manipulated, and also when physically manipulated and then administered in a manner not consistent with oral dosing. The dosage forms may also exhibit abuse resistant properties when administered in a manner intended to result in administration of the esketamine in a higher than therapeutic dose.
A method of treating depression comprising orally administering to a subject in need thereof, an immediate release tablet comprising esketamine or a pharmaceutically acceptable salt thereof, sodium bicarbonate in an amount of no more than 2.2 wt % and 2-(2-chlorophenyl)-2-(methylamino)-6-methylidenecyclohexan-1-one in an amount that is no more than 5.5 wt % after storage in accelerated conditions for at least 6 months.
Dependencies are inferred from the claim text.